Effectiveness of Dexmedetomidine Versus Sufentanil on Cerebral Oxygen Saturation in Patients With Traumatic Brain Injury
Status:
COMPLETED
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This randomized controlled clinical trial aims to evaluate the effectiveness of dexmedetomidine compared with sufentanil on cerebral oxygen saturation in patients with traumatic brain injury (TBI) undergoing surgery under general anesthesia. Cerebral oxygen saturation (rSO) will be monitored using Near-Infrared Spectroscopy (NIRS) to assess the impact of both anesthetic regimens on cerebral oxygenation and hemodynamic stability.
Patients meeting the inclusion criteria will be randomly assigned into two groups (1:1 ratio) using a simple random draw method.
Group A will receive dexmedetomidine 1 g/kg for induction, thiopental 5 mg/kg, and rocuronium 0.6 mg/kg, followed by maintenance with dexmedetomidine 0.3 g/kg/hour and sevoflurane 1-1.5 vol%.
Group B will receive sufentanil 0.2 g/kg for induction, thiopental 5 mg/kg, and rocuronium 0.6 mg/kg, followed by maintenance with sufentanil 0.2 g/kg/hour and sevoflurane 1-1.5 vol%. Both groups will receive intravenous paracetamol 1 g for analgesia at the end of surgery.
All patients will remain intubated postoperatively and will be transferred to the Intensive Care Unit (ICU) for monitoring. NIRS probes will be placed bilaterally on the cleaned frontal regions to measure rSO values preoperatively, intraoperatively, and postoperatively at 60 and 120 minutes after intervention.
Postoperative analgesia will consist of dexmedetomidine 0.3 g/kg/hour with paracetamol 1 g every 8 hours in the dexmedetomidine group, and sufentanil 0.1 g/kg/hour with paracetamol 1 g every 8 hours in the sufentanil group.
Clinical and hemodynamic parameters will be recorded throughout the perioperative period.
Data will be analyzed to compare cerebral oxygen saturation changes between the two groups, aiming to determine whether dexmedetomidine provides superior cerebral oxygenation compared with sufentanil in patients with traumatic brain injury undergoing neurosurgical procedures.